Quick Dispatch:
Your eccogene glp-1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your eccogene glp-1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies ships.
Need Help?
Questions about eccogene glp-1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for eccogene glp-1 Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies in your area.
AstraZeneca's Elecoglipron Advances in Oral GLP-1 Market | Alan Nafiev posted on the topic
23.92
-agonists-market-key-insight.png)
Glucagon-like Peptide-1 (GLP-1) Agonists Market Size and Companies
27.39
Elecoglipron Shows Positive Results in Phase 1b Trial in China | Eccogene posted on the topic
29.58
Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies
24.30
China's Eccogene Inks USD2 Billion Obesity Drug Deal With AstraZeneca
28.90
Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases
28.47
GLP-1s: The Second Serving
20.37
